News

Article

OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain

Key Takeaways

  • Urcosimod shows over two and a half years of stability in single-use ampoules, crucial for FDA approval.
  • The drug is in a phase 2b clinical trial for neuropathic corneal pain, with 48 patients enrolled.
SHOW MORE

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

(Image Credit: AdobeStock/yuz)

(Image Credit: AdobeStock/yuz)

OKYO Pharma announced positive data in the long-term stability of urcosimod (formerly known as OK-101) for the treatment of neuropathic corneal pain (NCP).

According to the company, urcosimod has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients. Urcosimod is currently in a phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial to treat NCP patients, which had the first patient dosed in October 2024.

Gary S Jacob, PhD, CEO of OKYO Pharma, and Raj Patil, PhD, chief scientific officer of OKYO Pharma, commented on the data in a press release from the company.

“Success for a drug in clinical development is not just about clinical data obtained from clinical trials but also requires a considerable amount of successful effort with what are called the chemistry, manufacturing, and controls (CMC) part of a successful submission package to the FDA,” said Jacob. "One of the major requirements for drug approval is that the drug is stable to degradation for a considerable period of time. This addresses the issue of shelf stability for a drug, and the fact that we have now established this for urcosimod is a critical positive step in meeting CMC requirements for a successful New Drug Application (NDA) with FDA.”

“Recently completed GMP stability assay testing of single-use ampoules containing urcosimod in ophthalmic solution, stored under refrigerated conditions, showed impressive stability (0.05% urcosimod – 94.8% and 0.1% urcosimod – 97.4%) after over two and a half years,” said Patil. “We are also conducting long-term stability testing of urcosimod at room temperature, and so far, the 3-month results at room temperature are at or above 100%.

OKYO recently filed an application for Fast Track designation with the US Food and Drug Administration (FDA) for urcosimod for the treatment of NCP. Urcosmid is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response.

References:
  1. OKYO Pharma announces positive data in long-term stability of urcosimod. Published March 31, 2025. Accessed March 31, 2025. https://www.globenewswire.com/news-release/2025/03/31/3052220/0/en/OKYO-Pharma-Announces-Positive-Data-in-Long-Term-Stability-of-Urcosimod.html
Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
Fasika Woreta, MD, MPH, Eugene de Juan, M.D. Professor of Ophthalmic Education at Wilmer Eye Institute’s Baltimore and Columbia locations, discusses the NMA meeting
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
© 2025 MJH Life Sciences

All rights reserved.